These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1171 related articles for article (PubMed ID: 18191511)
1. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Dadashzadeh S; Vali AM; Rezaie M Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511 [TBL] [Abstract][Full Text] [Related]
2. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan. Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756 [TBL] [Abstract][Full Text] [Related]
3. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. Li C; Wang C; Yang H; Zhao X; Wei N; Cui J J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269 [TBL] [Abstract][Full Text] [Related]
4. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471 [TBL] [Abstract][Full Text] [Related]
5. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Vali AM; Toliyat T; Shafaghi B; Dadashzadeh S Drug Dev Ind Pharm; 2008 Jan; 34(1):10-23. PubMed ID: 18214751 [TBL] [Abstract][Full Text] [Related]
6. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877 [TBL] [Abstract][Full Text] [Related]
7. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology. Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962 [TBL] [Abstract][Full Text] [Related]
8. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782 [TBL] [Abstract][Full Text] [Related]
9. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031 [TBL] [Abstract][Full Text] [Related]
10. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma. Kumar MR; Aithal BK; Udupa N; Reddy MS; Raakesh V; Murthy RS; Raju DP; Rao BS Drug Deliv; 2011; 18(7):511-22. PubMed ID: 21793763 [TBL] [Abstract][Full Text] [Related]
11. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies. Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385 [TBL] [Abstract][Full Text] [Related]
12. Vascular targeting of doxorubicin using cationic liposomes. Wu J; Lee A; Lu Y; Lee RJ Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230 [TBL] [Abstract][Full Text] [Related]
13. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556 [TBL] [Abstract][Full Text] [Related]
14. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). Parr MJ; Masin D; Cullis PR; Bally MB J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319 [TBL] [Abstract][Full Text] [Related]
15. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468 [TBL] [Abstract][Full Text] [Related]
16. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607 [TBL] [Abstract][Full Text] [Related]
17. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044 [TBL] [Abstract][Full Text] [Related]
18. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Kim JY; Kim JK; Park JS; Byun Y; Kim CK Biomaterials; 2009 Oct; 30(29):5751-6. PubMed ID: 19656559 [TBL] [Abstract][Full Text] [Related]
19. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125 [TBL] [Abstract][Full Text] [Related]
20. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]